Genetic knockout of either CXCR4 [22] or SDF-1a [23] is embryonic lethal in mice, with a failure to populate the bone marrow niche during development. Conditional deletion of either CXCR4 [24] or SDF-1a [25 ] results in a substantial hematopoietic cell egress from the bone marrow and impaired marrow retention of gene-deleted HSCs and HPCs after transplantation [25 ,26] .
Although numerous reports support a key role for the CXCR4/SDF-1a axis in hematopoietic cell retention/ trafficking/mobilization within the bone marrow niche, the predominant source of SDF-1a is still not clear.
Osteoblasts [35] recently showed reduced SDF-1a production in Col2.3-expressing osteoblasts with no reduction in Col2.3-negative stromal cells, suggesting that reduced osteoblast SDF-1a is a common mechanism of cytokine-induced mobilization. However, MendezFerrer et al. [31 ] , using a similar approach, showed substantially reduced SDF-1a in nestin þ MSC relative to a similar population of stromal cells described by Christopher et al. [35] , although a direct comparison to defined osteoblasts was not made. This is similar to findings that a mesenchymal precursor cell may form the hematopoietic niche [36 ] . Overall, these results suggest that heterogeneous cell populations expressing SDF-1a and other supportive factors create unique niches, each of which can be manipulated to facilitate mobilization. Defining the specific niche(s) responsible for SDF-1a production and HSC retention will aid in the development of future therapeutic strategies.
Osteoblasts, osteoclasts, osteomacs, and other operators
Osteoblasts express signaling molecules in addition to SDF-1a that may regulate HSC function and niche retention [37] [38] [39] [40] . More likely, mobilization is a complex process coordinated by a balance between cell populations in the bone marrow rather than specifically a function of a single cell lineage. Thus, model systems that target specific populations would be sufficient to induce mobilization, but not necessarily exclusive. Clearly, the cellular players and factors warrant further exploration.
As a prime example of cellular balance, osteoblasts and osteoclasts regulate bone formation/bone resorption, within the bone marrow niche. Kollet et al. [53] reported that RANK ligand treatment, which increases osteoclast activity, produces a moderate mobilization of HPCs. Similar results are also seen in an independent report [54 ] . Correspondingly, stress models such as bleeding or lipopolysaccharide treatment increased the number of osteoclasts that was coincident with HPC mobilization. G-CSF mobilization was decreased after inhibition of osteoclasts, by treatment with calcitonin or using a PTP e gene knockout model, further suggesting osteoclast involvement in G-CSF-mediated mobilization. The authors proposed that osteoclast-derived proteolytic enzymes, such as cathepsin K, degrade important niche interaction components including SDF-1a and OPN [53] . In a more recent study, they demonstrated reduced osteoclast maturation and activity in CD45 knockout mice that correlated with reduced mobilization to RANK ligand and G-CSF [55] .
In contrast, an earlier report demonstrated that although G-CSF increases osteoclast number and bone resorption in both BALB/c mice and humans, the increase in osteoclasts did not occur until 10-15 or 6-8 days, respectively, after treatment with G-CSF [56] , a finding also observed by others using similar systems [32, 57] . As G-CSF mobilization is typically evaluated after 4-5 days, the importance of osteoclasts to G-CSF-induced mobilization remains unclear. Furthermore, treatment of mice with bisphosphonates, which inhibit osteoclast activity and/or number, prior to G-CSF administration does not result in impaired mobilization [49 ,56] , and in fact, in one case, bisphosphonate treatment increased mobilization [49 ] . Of note, the endosteal bone surface, particularly underneath resorbing osteoclasts, is a significant source of extracellular calcium, and studies by Adams et al. [58] demonstrated that HSC expression of calciumsensing receptors mediates chemoattraction to soluble Ca 2þ . Calcium-sensing receptor knockout mice had reduced marrow HSC content and increased peripheral blood HSCs, perhaps suggesting that increased G-CSF mobilization seen in zoldronate-treated mice resulted from reduced calcium retention signaling within the niche. Although increased osteoclast activity can clearly induce mobilization, their role in G-CSF-mediated mobilization is not sufficiently defined and may not be a primary mechanism of mobilization. Figure 1 summarizes some of the key cellular components involved in HSC retention and subsequent mobilization following G-CSF treatment.
Hypoxia harbors hematopoiesis
Hematopoietic stem cells reside in hypoxic niches within the bone marrow [59] [60] [61] , and HSCs that reside in hypoxic niches have greater hematopoietic repopulating ability [62 ] . Stabilization of the transcription factor hypoxia inducible factor 1-a (HIF-1a) is a known physiological response to hypoxia, and HIF-1a has been shown to upregulate erythropoietin (EPO) production [63] , numerous cell proliferation and survival genes [64] [65] [66] , the angiogenic vascular endothelial growth factor (VEGF) [67] , and other genes. The hypoxic niche may maintain HIF-1a activity thereby maintaining HSCs [68] , a hypothesis supported by the fact that hypoxic conditions expand human HSC [69] and HPC populations [70] [71] [72] in vitro. In response to G-CSF, HIF-1a expression is increased [73 ] and both the hypoxic environment and HIF-1a expand within the marrow compartment [74] , with increased VEGF production; however, marrow vascular density and permeability are not increased [62 ] . In addition, HIF-1a is stabilized in peripheral blood HSCs acquired from G-CSF mobilized donors [75] . HIF-1a also increases SDF-1a production [76] and CXCR4 expression [77] , suggesting that hypoxia may be a physiological regulator of this important signaling axis. Of note, one report suggests that decreased osteoblast SDF-1a expression and reduced CXCR4 expression on bone marrow cells can be facilitated by osteoclasts activated by the hypoxia-mimetic CoCl 2 in vitro [54 ] . Recently, a population of marrow-derived very small embryonic-like stem cells was reported to mobilize as a result of intermittent hypoxia, coincident with an increase in plasma SDF-1a [78 ] , further suggesting that hypoxia may regulate HSC retention/trafficking. HIF-1a also prevents hematopoietic cell damage caused by reactive oxygen species (ROS) [79] , suggesting that the hypoxic niche helps maintain HSC lifespan. In slight contrast, another report demonstrated that enhanced c-Met activity promotes mobilization by activating mTOR and increasing ROS production in HSCs and HPCs [80 ] , whereas inhibition of mTOR with rapamycin reduced HSC mobilization [80 ,81] , suggesting that a small amount of ROS may be necessary for optimal mobilization. Knockout of the thioredoxin-interacting protein gene results in increased mobilization under stress conditions [82] , suggesting a role for oxygen tension and ROS in mobilization.
Nervous niche
The marrow microenvironment is highly innervated [83] , and catecholamine signaling can alter numerous physiological processes of immune cells [84] . A seminal study by Katayama et al. [30] demonstrated that G-CSF mobilization was reduced in chemically sympathectomized mice, mice treated with the b-blocker propanolol, or mice genetically deficient in the gene for dopamine bhydroxylase (Dbh), an enzyme that converts dopamine into norepinephrine, demonstrating that mobilization
At steady state (left panel), HSCs reside in bone marrow niches, closely associated with cells such as osteoblasts or nestin þ MSCs that express SDF1a and other supportive factors. Resident macrophages provide a positive supporting factor maintaining osteoblast and MSC activity. During G-CSF mobilization (right panel), G-CSF acts directly on the resident macrophages, causing them to transit away from the endosteal niche and reduces their number, and alters SNS signaling. This results in an attenuation of osteoblast function and a characteristic flattening and reduction of supportive factors like SDF-1a in the marrow, with an increase in plasma SDF-1a. Differentiation of MSCs into osteoblasts may be inhibited by G-CSF treatment. The role of both activated osteoclasts and neutrophils still remains unclear. G-CSF, granulocyte-colony stimulating factor; HSCs, hematopoietic stem cells; MSC, mesenchymal stem cell; SDF-1a, stromal cell-derived factor-1a; SNS, sympathetic nervous system. requires peripheral b 2 -adrenergic signals. This study also demonstrated that G-CSF attenuated osteoblast function, via the SNS, resulting in osteoblasts having a marked flattened appearance. Intriguingly, b 2 -adrenergic signaling can regulate osteoclast differentiation [85] and nestin þ MSCs are highly innervated [31 ] , perhaps suggesting that SNS signaling alters niche cell components through multiple mechanisms. In addition to the niche, human CD34 þ cells express b 2 -adrenergic and dopamine receptors that are upregulated by G-CSF [86] , and neurotransmitters serve as direct chemoattractants to hematopoietic cells [86] and increase CXCR4 expression [87] . Epinephrine treatment also results in mobilization [86] .
Signaling from b 3 -adrenergic receptors regulate circadian oscillations mediating norepinephrine release, CXCR4 expression, and SDF-1a production, leading to rhythmic egress of hematopoietic cells from the niche [88, 89] . Both b 2 and b 3 -adrenergic signals cooperate to regulate G-CSF-induced mobilization, although knockout of both only partially blocks mobilization [90 ] and does not abrogate mobilization by Clo-lip [50 ] , suggesting multiple/parallel pathways regulating mobilization. b 2 -Adrenergic signaling also upregulates osteoblast vitamin D receptors (VDRs) and it was recently demonstrated that expression of VDR is necessary for the G-CSFinduced suppression of osteoblast function and that HSC mobilization is reduced in VDR knockout mice [91 ] . VDR is also regulated by circadian rhythms [92] , demonstrating further complexity in interconnected mobilization mechanisms.
Fatty acids for the future
Studies exploring the role of SNS signaling in G-CSFmediated mobilization began in mice defective in ceramide galactosyltransferase (CGT), an enzyme that synthesizes galactocerebrosides, major lipid components of myelin sheaths and are important for proper nerve conduction [30] . Mice deficient in the related enzyme galactocerbrosidase (GALC) have a defective niche in which transplanted HSCs fail to engraft [93 ] . Sphingosine-1-phosphate (S1P) and ceramide, which affect a wide variety of cellular processes, are part of the GALC metabolic pathway [94] . HSCs and HPCs express the S1P receptor S1P1 [95] , and S1P1 signaling alters CXCR4/ SDF-1a signaling and chemotaxis [95] [96] [97] . S1P directs trafficking of immature B cells [98 ] and trafficking of HSCs and HPCs from blood, bone marrow, and lymph tissues [1] . A recent report by Ratajczak et al. [99 ] suggests that plasma S1P increases following G-CSF administration and directs peripheral chemoattraction, facilitating mobilization. An increase in S1P in peripheral blood coordinated with a decrease in marrow was recently reported, suggesting the formation of an S1P gradient driving mobilization [100] , or perhaps even a dual lipid action mediated by both S1P and ceramide concentrations in peripheral blood and bone, respectively [101] . If S1P signaling through S1P1 regulates G-CSF mobilization, then co-treatment with an S1P1 antagonist, like FTY720, would be expected to reduce G-CSF mobilization. This was indeed reported in one case [100] ; however, others report no decreases in G-CSF mobilization in FTY720-treated mice [1, 102] . Further studies evaluating the role of S1P and ceramide will aid in determining their functional importance in hematopoietic mobilization, and whether agents modifying S1P1 signaling, like the S1P agonist SEW2871, can be utilized as an adjunctive therapeutic agent in mobilization.
In addition to the sphingolipids, other bioactive lipids have the capacity to regulate hematopoiesis, including eicosanoids. We recently reported that prostaglandin E 2 (PGE 2 ) regulates CXCR4 expression on HSCs and HPCs and facilitates their chemoattraction to SDF-1a and homing [103] . Like many lipid systems, homeostasis is maintained by a balance of signaling among eicosanoids with several of the eicosanoids acting in opposing manners. We also showed that agonism of cannabinoid receptors, receptors for the eicosanoid-related endocannabinoids, acts in an opposing fashion to PGE 2 signaling, decreasing adhesion molecule expression and CXCR4, and enhancing G-CSF mobilization [104 ] . Two separate reports by Jiang et al. [105 ,106 ] have also demonstrated that cannabinoid signaling mediates mobilization, and that endocannabinoids are expressed in bone marrow and increase HPC migration and proliferation in vitro. Another report demonstrated that cannabinoids mobilize myeloid-derived suppressor cells, with a possible role for endogenous G-CSF production [107 ] . It is interesting to note that cannabinoid receptors are physically associated with b 2 -adrenergic receptors and modulate adrenergic signaling [108 ,109 ] , possibly suggesting a SNS/cannabinoid mechanistic link. With the abundance of FDAapproved compounds modulating eicosanoid signaling, additional studies exploring their role in mobilization are likely to lead to new therapeutic strategies.
Conclusion
Although significant progress has been made in defining the mechanisms mediating mobilization by G-CSF, a complete understanding remains elusive. Do osteoblasts comprise the important hematopoietic niche suppressed by G-CSF administration, or is it innervated nestin þ MSCs, or a heterogeneous population of cells forming several unique niches? Experimental animal models designed to explore mobilization have significantly advanced the field, but manipulation of a specific system, although sufficient to mimic or block mobilization by G-CSF, may not tell the whole story. Although both genetic alteration of the SNS or macrophages can mediate mobilization, neither regulates the niche exclusively during mobilization and other parallel or intersecting pathways are likely involved. Combination therapies manipulating multiple mechanistic pathways should be explored to not only maximally mobilize hematopoietic cells for transplant, but also possibly to mobilize other potential therapeutically efficacious cell populations.
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51
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